Management to host a conference call and webcast at 4:30 PM ET on that day
Novus Therapeutics, Inc. ("Novus") (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation, as well as those living with immunological diseases, today announced that the company will report its financial results for the three and nine months ended September 30, 2020, after the market close on Monday, November 16, 2020. Management will host a corporate update conference call and webcast at 4:30 PM Eastern Time the same day.
Conference Call Details |
||||
Monday, November 16, at 4:30 PM Eastern Time / 1:30 PM Pacific Time |
||||
Toll Free: |
877-407-3982 |
|||
International: |
201-493-6780 |
|||
Conference ID: |
13713171 |
|||
Webcast: |
http://public.viavid.com/index.php?id=142451 |
|||
About Novus Therapeutics
Novus Therapeutics, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cell-based transplant, and for people with autoimmune and neurodegenerative disease. Novus is headquartered in Irvine, California. For more information, please visit the company’s website at www.novustherapeutics.com.
Follow Novus Therapeutics on social media: @Novus_Thera and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201110006234/en/
Contacts
Media
Amanda Sellers
asellers@vergescientific.com
301-332-5574
Investors
Bruce Mackle
LifeSci Advisors. LLC
bmackle@lifesciadvisors.com
929-469-3859
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.